Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26140596 | 0.88 | HRH3 (0.53) | HRH3KCNH2CYP2D6 | |
| SCHEMBL21738162 | 0.83 | HRH3 (0.38) | HRH3KCNH2CYP2D6CYP1A2 | |
| SCHEMBL26139029 | 0.83 | HRH3 (0.44) | HRH3KCNH2CYP2D6SIGMAR1 | |
| SCHEMBL21738164 | 0.81 | MEN1 (0.41) | HRH3KCNH2CYP2D6TDP1 | |
| SCHEMBL23583248 | 0.80 | HRH3 (0.41) | HRH3KCNH2CYP2D6 | |
| SCHEMBL26139054 | 0.79 | HRH3 (0.49) | HRH3KCNH2CYP2D6EPHX2 | |
| SCHEMBL26139052 | 0.78 | HRH3 (0.40) | HRH3KCNH2CYP2D6NPSR1 | |
| SCHEMBL25858704 | 0.78 | HRH3 (0.48) | HRH3HSD11B1 | |
| SCHEMBL25862987 | 0.77 | HTR1A (0.40) | CYP1A2TDP1HSD11B1HTR1ASIGMAR1 | |
| SCHEMBL21846687 | 0.76 | ALDH1A1 (0.43) | HRH3KCNH2CYP2D6HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | HRH3 870/4885KCNH2 4282/4885CYP2D6 2635/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | HRH3 932/4885KCNH2 4350/4885CYP2D6 2809/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | HRH3 932/4885KCNH2 4350/4885CYP2D6 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.